Ozempic (semaglutide) is second only to Humira (adalimumab) in sales, according to the IQVIA vice president of industry relations and a frequent speaker at conference. And for newly launched drugs, sales figures for Mounjaro (tirzepatide) are second only to what they were for Harvoni (ledipasvir and sofosbuvir), a hepatitis C antiviral, when the hepatitis C antivirals were new.
Doug Long has seen it before.
“The introduction of the HIV drugs, followed by the hepatitis C drugs. Now you have the GLP-1s,” said the IQVIA vice president of industry relations in a short interview after delivering one of his trademark presentations on pharmaceutical and healthcare trends that feature rapid-fire delivery of voluminous slide decks. “I call them tsunamis.”
Still, the surge in the sales of the GLP-1 drugs is the “topic of conversation in every (healthcare) trade organization today. It is really a game changer,” Long said during his presentation Thursday at the 2023 PBMI Annual National Conference in Orlando.
Long’s sweeping, data-rich review also touched on healthcare utilization after the COVID-19 pandemic, spending on specialty drugs, increased spending on drugs for mental health and drug shortages.
The now-famous GLP-1s include Ozempic (semaglutide), Wegovy (also semaglutide but a higher dose) and Mounjaro (tirzepatide).
Long showed sales data collected by IQVIA that identified Ozempic as second only to Humira in nondiscounted sales — $20.6 billion in the moving annual target (MAT) in June 2023 compared with $32.7 billion for Humira (adalimumab). Sales have of Ozempic, which has trended as a topic on TikTok, soared 78.4% in 12 month prior to June. “Thank you social media for that” Long quipped.
Mounjaro, which was approved by the FDA as a diabetes drug in May 2022 but is being used off-label for weight loss, ranked number 11 on Long’s list of top drugs by nondiscounted spend at $8.4 billion in sales, and Long said Mounjaro was second only to Harvoni (ledipasvir and sofosbuvir), a hepatitis C drug, in sales during the first 10 months on the market.
Spending on the GLP-1s as a class of drugs is also on steep northward pitch in Long’s telling, increasing from $8.9 billion in 2018 to $35.2 billion in 2022.Most of prescriptions are written for women (77%) and middle aged (59% for individuals ages 40-59). Trulicity (dulaglutide), Rybelsus (semaglutide tablets), Victoza (liraglutide) and several other drugs are in the GLP-1 class but Ozempic and Mounjaro are responsible for most of the growth of the sales of the class, Long said.
Health plans and PBMs have taken steps to rein in the number of GLP-1 prescriptions by, for example, requiring patients to try other medications (which is called step therapy) before taking Ozempic or Mounjaro. But Long said during the brief interview that he expected to insurers to cover the GLP-1 drugs because of the large proportion of Americas who are overweight.
Here are other topics that Long covered during his presentation: